Developer docs
API playgroundTry for free, no card

Search company profiles

Kivu Bioscience

Full company profile

uuid0000rc2

Namestring
Kivu Bioscience
Legal namestring
Kivu Bioscience, Inc.
Company typeenum
Private
Founded yearint
2024
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Mateo, United States
HQ citystring
San Mateo
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antibody-drug conjugates, oncology therapeutics, targeted cancer therapy, ADC development, biopharmaceutical pipeline
Industry3 codes
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical and Medicine Manufacturing3254
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Commercial Physical & Biological Research8731
Product category
Antibody-Drug Conjugates
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1ADC Development and Licensing
TypeLicensing Royalties
Description

Kivu Bioscience is a clinical-stage biotechnology company developing next-generation ADCs for oncology. The company does not yet have commercialized products and is pre-revenue. Future revenue is expected to come from licensing agreements, co-development partnerships, and potential commercialization of its ADC pipeline candidates.

kivubioscience.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Kivu Bioscience is a clinical-stage biotechnology company developing a pipeline of next-generation antibody-drug conjugates (ADCs) for difficult-to-treat solid tumors. The company licenses Synaffix's GlycoConnect site-specific conjugation and HydraSpace hydrophilic linker technologies and combines them with proprietary payloads such as SYNtecan E topoisomerase inhibitor to produce homogeneous, plasma-stable ADCs with improved therapeutic index. Lead candidates KIVU-107 (PTK7) and KIVU-305 (CEACAM5) are in Phase 1 clinical development, with additional candidates KIVU-495 and KIVU-202 in earlier-stage development.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • KIVU-107 demonstrated potent antigen-specific cytotoxicity with rapid internalization in vitro and durable complete tumor regressions after a single dose in mouse xenograft models
+2 more records
Product overview1 text field

Kivu Bioscience is a clinical-stage biotechnology company developing a pipeline of next-generation antibody-drug conjugates (ADCs) for difficult-to-treat cancers. The company's proprietary ADC platform leverages differentiated linker and payload technologies including Synaffix's GlycoConnect® site-specific conjugation and HydraSpace® linker technologies, along with proprietary clinically validated payloads, to enhance tumor selectivity and efficacy while minimizing off-target toxicity. The pipeline includes four ADC candidates: KIVU-107 (PTK7-targeting, Phase 1), KIVU-305 (CEACAM5-targeting, Phase 1), KIVU-495 (undisclosed target, development candidate), and KIVU-202 (development candidate).

Product and service4 records
1KIVU-107
CategoryADC candidate (PTK7 target)
Description

A next-generation PTK7-targeting antibody-drug conjugate (ADC) built using GlycoConnect site-specific conjugation and HydraSpace linker technologies, designed to deliver potent cytotoxic activity in PTK7-expressing solid tumors with improved safety and tolerability compared to earlier-generation ADCs. Currently in Phase 1 clinical development.

2KIVU-305
CategoryADC candidate (CEACAM5 target)
Description

A next-generation CEACAM5-targeted ADC composed of a humanized antibody conjugated via site-specific GlycoConnect technology to a HydraSpace-linked SYNtecan E topoisomerase inhibitor payload, incorporating Fc-silencing and an optimized DAR4 configuration for enhanced plasma stability and tumor exposure. Currently in Phase 1 clinical development.

3KIVU-495
CategoryADC candidate (undisclosed target)
Description

An ADC development candidate with an undisclosed target, currently at the development candidate stage for solid tumors.

4KIVU-202
CategoryADC candidate
Description

An ADC candidate in development for solid tumors.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2025-06-02
Description

Manufacturing partnership with Sterling Pharma Solutions to produce cGMP-quality material for Phase 1 clinical trials of KIVU-107. Sterling manufactures cGMP clinical material at its dedicated bioconjugation facility in Deeside, UK, including process familiarisation, analytical development, process optimisation, and scale-up activities.

Strategic tierCoreTypeTechnology or Integration
Description

Technology licensing partnership for GlycoConnect® and HydraSpace® site-specific conjugation technologies used in Kivu's ADC platform. Synaffix was acquired by Lonza.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing a pipeline of ADCs for hematologic and solid tumors, with FDA-approved Zynlonta. Direct competitor in the ADC oncology space targeting similar solid tumor indications with comparable linker/payload approaches.

TypeDirect peer
Description

Clinical-stage ADC-focused biotech developing next-generation ADCs with proprietary platforms (Dolasynthen, Immunosynthen). Highly comparable as a similarly-sized ADC pure-play pursuing differentiated linker and payload technologies.

TypeDirect peer
Description

Clinical-stage oncology biotech developing ADCs and immunotherapies. Comparable as a peer ADC developer with similar stage of pipeline assets and target validation approach for solid tumors.

TypeEmerging player
Description

Emerging ADC platform company with proprietary conjugation and linker technologies (Tub-tag, P5). Comparable as a technology-driven ADC developer focused on site-specific conjugation and stable linkers, overlapping with Kivu's Synaffix-licensed approach.

TypeEmerging player
Description

Clinical-stage ADC company developing next-generation ADCs for solid tumors. Comparable emerging player with proprietary linker-payload technology targeting similar indications and patient populations as Kivu.

TypeBroad incumbent
Description

Global pharmaceutical company that pioneered Enhertu and Datroway ADCs in partnership with AstraZeneca. Broad incumbent setting the benchmark Kivu aims to outperform on therapeutic index, and a likely potential partner or acquirer.

TypeBroad incumbent
Description

Global pharma that co-developed Enhertu and Datroway with Daiichi Sankyo and has aggressively acquired ADC companies (Gracell, Fusion Pharmaceuticals). Comparable as a deep-pocketed incumbent shaping the ADC landscape and a likely BD counterparty.

TypeBroad incumbent
Description

Global pharma that acquired Seagen for $43B to anchor its ADC franchise. Comparable as a major incumbent in the ADC space and likely partnership or licensing counterparty for clinical-stage assets like Kivu's pipeline.

TypeBroad incumbent
Description

Global pharma with multiple ADC programs (including ABBV-319 led by Kivu's Associate Director Anderson Chang) and the ImmunoGen acquisition (Elahere). Comparable incumbent and notable given multiple Kivu executives previously led oncology at AbbVie.

TypeBroad incumbent
Description

ADC pioneer acquired by AbbVie, with FDA-approved Elahere for ovarian cancer. Comparable as an established ADC platform now integrated into a major pharma, representing the kind of strategic outcome available to successful ADC developers like Kivu.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles19 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Kivu Bioscience

Antibody-Drug Conjugateskivubioscience.com

Kivu Bioscience firmographics

Firmographics
Name
Kivu Bioscience
Legal name
Kivu Bioscience, Inc.
Website
https://kivubioscience.com
Company type
Private
Founded year
2024
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Kivu Bioscience industry classification

Industry
Product category
Antibody-Drug Conjugates
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Antibody-drug conjugates
  • Oncology therapeutics
  • Targeted cancer therapy
  • ADC development
  • Biopharmaceutical pipeline

Where Kivu Bioscience is headquartered

Location

Headquarters

HQ city
San Mateo
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Kivu Bioscience business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. ADC Development and Licensing: Kivu Bioscience is a clinical-stage biotechnology company developing next-generation ADCs for oncology. The company does not yet have commercialized products and is pre-revenue. Future revenue is expected to come from licensing agreements, co-development partnerships, and potential commercialization of its ADC pipeline candidates.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Kivu Bioscience product offering

Product offering

Core offering

Kivu Bioscience is a clinical-stage biotechnology company developing a pipeline of next-generation antibody-drug conjugates (ADCs) for difficult-to-treat solid tumors. The company licenses Synaffix's GlycoConnect site-specific conjugation and HydraSpace hydrophilic linker technologies and combines them with proprietary payloads such as SYNtecan E topoisomerase inhibitor to produce homogeneous, plasma-stable ADCs with improved therapeutic index. Lead candidates KIVU-107 (PTK7) and KIVU-305 (CEACAM5) are in Phase 1 clinical development, with additional candidates KIVU-495 and KIVU-202 in earlier-stage development.

Product overview

Kivu Bioscience is a clinical-stage biotechnology company developing a pipeline of next-generation antibody-drug conjugates (ADCs) for difficult-to-treat cancers. The company's proprietary ADC platform leverages differentiated linker and payload technologies including Synaffix's GlycoConnect® site-specific conjugation and HydraSpace® linker technologies, along with proprietary clinically validated payloads, to enhance tumor selectivity and efficacy while minimizing off-target toxicity. The pipeline includes four ADC candidates: KIVU-107 (PTK7-targeting, Phase 1), KIVU-305 (CEACAM5-targeting, Phase 1), KIVU-495 (undisclosed target, development candidate), and KIVU-202 (development candidate).

Differentiator

Problem solved

Functional benefit

Products and services

  • KIVU-107 A next-generation PTK7-targeting antibody-drug conjugate (ADC) built using GlycoConnect site-specific conjugation and HydraSpace linker technologies, designed to deliver potent cytotoxic activity in PTK7-expressing solid tumors with improved safety and tolerability compared to earlier-generation ADCs. Currently in Phase 1 clinical development.
  • KIVU-305 A next-generation CEACAM5-targeted ADC composed of a humanized antibody conjugated via site-specific GlycoConnect technology to a HydraSpace-linked SYNtecan E topoisomerase inhibitor payload, incorporating Fc-silencing and an optimized DAR4 configuration for enhanced plasma stability and tumor exposure. Currently in Phase 1 clinical development.
  • KIVU-495 An ADC development candidate with an undisclosed target, currently at the development candidate stage for solid tumors.
  • KIVU-202 An ADC candidate in development for solid tumors.

Quantifiable outcome

  • KIVU-107 demonstrated potent antigen-specific cytotoxicity with rapid internalization in vitro and durable complete tumor regressions after a single dose in mouse xenograft models
  • +2 more outcomes

Companies that use Kivu Bioscience

Customer profile

Segments1 record

Ideal customer profiles1 record

Kivu Bioscience technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Kivu Bioscience partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Sterling Pharma SolutionscoreImplementation/ SI/ Consulting Partner · 2 June 2025Manufacturing partnership with Sterling Pharma Solutions to produce cGMP-quality material for Phase 1 clinical trials of KIVU-107. Sterling manufactures cGMP clinical material at its dedicated bioconjugation facility in Deeside, UK, including process familiarisation, analytical development, process optimisation, and scale-up activities.
  • SynaffixcoreTechnology or IntegrationTechnology licensing partnership for GlycoConnect® and HydraSpace® site-specific conjugation technologies used in Kivu's ADC platform. Synaffix was acquired by Lonza.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Kivu Bioscience competitors and assessment

Company assessment

Direct peers

  • ADC Therapeutics: Clinical-stage biotech developing a pipeline of ADCs for hematologic and solid tumors, with FDA-approved Zynlonta. Direct competitor in the ADC oncology space targeting similar solid tumor indications with comparable linker/payload approaches.
  • Mersana Therapeutics: Clinical-stage ADC-focused biotech developing next-generation ADCs with proprietary platforms (Dolasynthen, Immunosynthen). Highly comparable as a similarly-sized ADC pure-play pursuing differentiated linker and payload technologies.
  • Pyxis Oncology: Clinical-stage oncology biotech developing ADCs and immunotherapies. Comparable as a peer ADC developer with similar stage of pipeline assets and target validation approach for solid tumors.

Emerging players

  • Tubulis: Emerging ADC platform company with proprietary conjugation and linker technologies (Tub-tag, P5). Comparable as a technology-driven ADC developer focused on site-specific conjugation and stable linkers, overlapping with Kivu's Synaffix-licensed approach.
  • ProfoundBio: Clinical-stage ADC company developing next-generation ADCs for solid tumors. Comparable emerging player with proprietary linker-payload technology targeting similar indications and patient populations as Kivu.

Broad incumbents

  • Daiichi Sankyo: Global pharmaceutical company that pioneered Enhertu and Datroway ADCs in partnership with AstraZeneca. Broad incumbent setting the benchmark Kivu aims to outperform on therapeutic index, and a likely potential partner or acquirer.
  • AstraZeneca: Global pharma that co-developed Enhertu and Datroway with Daiichi Sankyo and has aggressively acquired ADC companies (Gracell, Fusion Pharmaceuticals). Comparable as a deep-pocketed incumbent shaping the ADC landscape and a likely BD counterparty.
  • Pfizer: Global pharma that acquired Seagen for $43B to anchor its ADC franchise. Comparable as a major incumbent in the ADC space and likely partnership or licensing counterparty for clinical-stage assets like Kivu's pipeline.
  • AbbVie: Global pharma with multiple ADC programs (including ABBV-319 led by Kivu's Associate Director Anderson Chang) and the ImmunoGen acquisition (Elahere). Comparable incumbent and notable given multiple Kivu executives previously led oncology at AbbVie.
  • ImmunoGen (AbbVie): ADC pioneer acquired by AbbVie, with FDA-approved Elahere for ovarian cancer. Comparable as an established ADC platform now integrated into a major pharma, representing the kind of strategic outcome available to successful ADC developers like Kivu.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights6 records

Customer concentration

Kivu Bioscience social profiles

Digital presence

Kivu Bioscience financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Kivu Bioscience leadership team

Management profile

Number of profiles

Profiles19 records

Kivu Bioscience funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Kivu Bioscience M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kivu Bioscience

What does Kivu Bioscience do?

Kivu Bioscience is a clinical-stage biotechnology company developing a pipeline of next-generation antibody-drug conjugates (ADCs) for difficult-to-treat solid tumors. The company licenses Synaffix's GlycoConnect site-specific conjugation and HydraSpace hydrophilic linker technologies and combines them with proprietary payloads such as SYNtecan E topoisomerase inhibitor to produce homogeneous, plasma-stable ADCs with improved therapeutic index. Lead candidates KIVU-107 (PTK7) and KIVU-305 (CEACAM5) are in Phase 1 clinical development, with additional candidates KIVU-495 and KIVU-202 in earlier-stage development.

Is Kivu Bioscience a public or private company?

Kivu Bioscience is a private company. It is classified as venture growth investor backed and is currently operating.

When was Kivu Bioscience founded?

Kivu Bioscience was founded in 2024. It employs 11 to 50 people.

Where is Kivu Bioscience based?

Kivu Bioscience is headquartered in San Mateo, United States, in the North America region.

How does Kivu Bioscience make money?

One revenue line is on record: ADC Development and Licensing.

Who are Kivu Bioscience's main competitors?

Direct peers on record are ADC Therapeutics, Mersana Therapeutics and Pyxis Oncology. Emerging players are Tubulis and ProfoundBio. Broad incumbents are Daiichi Sankyo, AstraZeneca, Pfizer, AbbVie and ImmunoGen (AbbVie).

Does Kivu Bioscience have an API?

No public API is recorded for Kivu Bioscience.

What industry is Kivu Bioscience in?

Kivu Bioscience's product category is Antibody-Drug Conjugates. Its primary akta.pro industry code is HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates, with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceBIO 2026: As ADCs evolve, experts say ‘wellness’ needs to be factored into patient survivalThe biopharma industry is advancing antibody-drug conjugates (ADCs) into earlier lines of cancer treatment, prompting experts at the BIO International Convention to urge developers to prioritize patient quality of life alongside efficacy. Panelists emphasized that future clinical trials should measure "wellspan" — not just how long patients survive, but how well they live during and after treatment — with companies like Kivu Bioscience and Zymeworks actively working on improving ADC design. New advancements in linkers, payloads, and applications beyond oncology into autoimmune diseases were discussed as key areas of innovation.BioSpaceHow To Shine As Biotech Comes Back From the BrinkBioSpace is hosting a virtual event featuring three early-stage biotech CEOs—Andy Orth of City Therapeutics, Eric Green of Trace Neuroscience, and Mo Trikha of Kivu Bioscience—who will discuss strategies for navigating the volatile biotech market and advancing the next generation of medicines. The article frames the discussion against a backdrop of returning M&A activity and IPOs in the biotech sector. The event appears designed to provide industry perspective rather than report on specific corporate developments.Business Wire BlogKivu Bioscience Appoints Brunilda Shtylla as Chief Business OfficerKivu Bioscience, a clinical-stage biotechnology company developing antibody-drug conjugates for difficult-to-treat cancers, has appointed Brunilda Shtylla as Chief Business Officer. Shtylla brings over 25 years of experience, most recently serving as CBO at Sutro Biopharma where she helped secure more than $5.5 billion in total deal value through collaborations and partnerships. She will lead corporate strategy, business development, and partnership initiatives as the company prepares to advance its second ADC candidate into clinical development.Business Wire BlogKivu Bioscience Presents KIVU-305 Preclinical Data at World ADC London 2026 and Advances into Phase 1 Clinical TrialKivu Bioscience presented preclinical data for its CEACAM5-targeted antibody-drug conjugate KIVU-305 at World ADC London 2026, while simultaneously receiving Human Research Ethics Committee approval and Clinical Trial Notification clearance in Australia to initiate a first-in-human Phase 1 clinical trial. The preclinical results demonstrated selective binding to tumor cells, potent cytotoxicity with bystander killing activity, strong anti-tumor efficacy across multiple xenograft models including chemotherapy-resistant tumors, and favorable pharmacokinetics with high plasma stability. KIVU-305 represents Kivu's second ADC program advancing into clinical development, utilizing site-specific GlycoConnect® conjugation and HydraSpace® linker technology designed to improve stability and widen the therapeutic window.Startus-insightsTop 25 Fastest Growing Tech Companies to Watch [2026]A list of 25 fastest-growing tech companies for 2026 includes Kivu Bioscience, Neolix, and Averna Therapeutics, with funding details. The companies span biotech, AI, energy storage, and software, with funding ranging from seed to over $600 million. The list highlights Asia-Pacific and North America as leading regions.STATUp and down the ladder: The latest comings and goingsKivu Bioscience has hired Sophia Randolph as chief medical officer. Ed Silverman, a senior writer at STAT, has been covering the pharmaceutical industry for nearly three decades and authors the Pharmalittle and Pharmalot newsletters. The article solicits reader submissions about personnel changes in the pharmaceutical sector.Business Wire BlogKivu Bioscience Appoints Sophia Randolph, M.D., Ph.D., as Chief Medical OfficerKivu Bioscience announced the appointment of Sophia Randolph, M.D., Ph.D. as Chief Medical Officer. Dr. Randolph brings over 20 years of oncology drug development experience, having previously served as CMO at ALX Oncology and held leadership roles at Pfizer Oncology and Merck. The appointment is aimed at advancing the company's next-generation antibody-drug conjugate (ADC) programs for difficult-to-treat cancers into clinical trials.Business Wire BlogKivu Bioscience Presents Preclinical Data for KIVU-107 Demonstrating Potent and Durable Anti-Tumor Activity and a Wide Therapeutic Index at World ADC San Diego 2025Kivu Bioscience announced it will present preclinical data for its lead ADC candidate KIVU-107 at the 16th World ADC San Diego conference on November 3-6, 2025, featuring both oral and poster presentations on the PTK7-targeting antibody-drug conjugate. The preclinical studies demonstrated potent and durable anti-tumor activity with complete tumor regressions in xenograft models, a wide therapeutic index, and favorable tolerability in repeat-dose GLP toxicology studies in non-human primates. The company plans to initiate a Phase 1 clinical study of KIVU-107 this quarter, positioning the candidate as a potential best-in-class next-generation ADC for difficult-to-treat cancers.